Shinohara Y, Imanishi M, Nishioka T, Uemura T, Kanda H, Matsuura T, Akiyama T, Kurita T
Department of Urology, Kinki University School of Medicine.
Nihon Hinyokika Gakkai Zasshi. 1992 Feb;83(2):236-42. doi: 10.5980/jpnjurol1989.83.236.
Deoxyspergualin (DSG), which is a new immunosuppressive drug developed in Japan, is expected to be an immunosuppressant for the treatment of rejection, because it has immunosuppressive action different from that of other drugs. In the present study we used DSG to treat renal allograft rejection of in total 17 cases; 6 cases with acute rejection, 8 with chronic rejection and 3 with acute on chronic rejection. We infused DSG very slowly over 3 hours at a dose of 3-7 mg/kg/day for 5-7 days. Four cases (44.4%) with acute or acute on chronic rejection showed excellent response to DSG, three cases (33.3%) showed fair response and two cases (22.3%) did not respond at all. We also used DSG in patients with chronic rejection. In many of them, the increase in serum creatinine was suppressed. Ten of the total patients (58.8%) developed side effects including leukocytopenia, thrombocytopenia, numbness of the fact etc. No patients needed discontinuation of DSG. From the above results, we think that DSG is a safe and effective drug to treat acute rejection. Furthermore, we could get the results which suggest that DSG is effective for the treatment of chronic rejection.
去氧精胍菌素（DSG）是日本研发的一种新型免疫抑制药物，因其具有与其他药物不同的免疫抑制作用，有望成为治疗移植排斥反应的免疫抑制剂。在本研究中，我们使用DSG治疗了总共17例肾移植排斥反应患者，其中急性排斥反应6例，慢性排斥反应8例，慢性排斥反应急性发作3例。我们以3 - 7毫克/千克/天的剂量，在3小时内非常缓慢地输注DSG，持续5 - 7天。4例（44.4%）急性或慢性排斥反应急性发作的患者对DSG表现出极佳的反应，3例（33.3%）表现出一般反应，2例（22.3%）则完全没有反应。我们还将DSG用于慢性排斥反应患者，其中许多患者血清肌酐升高得到了抑制。总共有10例患者（58.8%）出现了副作用，包括白细胞减少、血小板减少、面部麻木等。没有患者需要停用DSG。从上述结果来看，我们认为DSG是治疗急性排斥反应的一种安全有效的药物。此外，我们还得到了表明DSG对治疗慢性排斥反应有效的结果。
